| Autor: |
Collado MV; Sección Inmunología, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina. E-mail: vicocollado@hotmail.com., Gargiulo MLÁ; Sección Inmunología, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina., Gómez R; Hospital de Clínicas Gral. José de San Martín, Buenos Aires, Argentina., Gómez G; Sección Inmunología, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina., Pérez N; Sección Inmunología, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina., Suarez L; Sección Inmunología, Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina., Taratuto AL; Consultoría en Neuropatología y Patología Neuromuscular, Instituto de Investigaciones Neurológicas-FLENI, Hospital Nacional de Pediatría J.P Garrahan, Buenos Aires, Argentina., Aruj P; Sección Neumonología, Instituto de Investigaciones Médicas Alfredo Lanari, UBA, Buenos Aires, Argentina. |
| Abstrakt: |
Dematomyositis is an idiopathic inflammatory myopathy with a variable clinical spectrum. In recent years, a number of myositis-specific antibodies have been identified including anti-MDA5, which is us eful for diagnosis, prognosis and classification of the diverse clinical forms of the disease. This antibody is associated with cutaneous ulcers, rapidly progressive interstitial lung disease, early mortality and poor prognosis, so the detection of this antibody in a suitable clinical context, raises the need for an aggressive immunosuppressive treatment. We describe a case of dermatomyositis classified as hypomyopathic (i.e. involving mild muscle weakness), presenting specific skin lesions, interstitial lung disease, and presence of anti-MDA5 antibody that had a favorable response to combined treatment with cyclophosphamide, gamma globulin and corticosteroids. |
